ECEngela Helena Conradie

Engela Helena Conradie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Engela Helena Conradie has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improving access to rare disease diagnostics in Africa: insights from a multinational pilot study

    by Albe Carina Swanepoel, Christian Johannes Hendriksz, Renson Mukhwana, Abiola Oduwole, Asmahan T. Abdalla, Emmanuel Ameyaw, Kandi-Catherine Muze, Andrew Auruku, Felix Pinto, Dipesalema Joel, et al.

    Background: Rare diseases (RDs) in Africa face challenges such as limited diagnosis, expertise, and treatment. FYMCA Medical Ltd., the International Gaucher Alliance (IGA) and the Centre for Human Metabolomics (CHM) at North‒West University (NWU) launched a pilot study in 2022 to create an African RD diagnosis network, focusing on training clinicians and testing dried blood spot (DBS) samples for 6 lysosomal storage disorders (LSDs). The pilot study spanned eight sub-Saharan African countries (Nigeria, Ghana, Tanzania, Kenya, Mozambique, Uganda, Botswana, and Sudan), with samples sent to South Africa for analysis. Clinician training at the CHM was well received, with positive feedback suggesting hybrid learning for future sessions. Results: The project registered 56 samples in 27 months; Gaucher disease was most common. MPS II was the most prevalent MPS condition, with a prevalence resembling Eastern hemisphere patterns. Genetic variants were consistent with previous studies, but Fabry diagnoses were rare, which indicates the need for more focused programs. Conclusions: The high diagnostic yield for LSDs highlights the importance of targeted training and DBS cards for genetic testing. Challenges included sample integrity, referral gaps, and logistical delays. Addressing these barriers and fostering ongoing clinician engagement will enhance diagnostic capacity, whereas presenting findings at an African symposium will increase awareness.

  • Recruitment Strategies for a Nonhospital-Based Academic Rare Disease Biobank in South Africa

    by Engela H. Conradie, Varushka Acton, Albe C. Swanepoel

    Introduction: Rare disease research in South Africa (SA) faces significant challenges, including limited prioritization and awareness, which hinder advancements in patient care and scientific discovery. This article explores the recruitment strategies employed by the Centre for Human Metabolomics (CHM) Biobank, a nonhospital-based academic rare disease biobank, to address these challenges. Methods: We explain the consent process and documents as well as the three recruitment models employed, namely (1) Recruitment via referring clinician, (2) implementation of monthly diagnostic follow-up sessions, and (3) recruitment of patients for specific projects through clinic-based recruitment drives. Discussion: We discuss the benefits as well as the challenges of each model. Challenges included clinician and patient time constraints, distrust from current consent practices, and limited public awareness. We elaborate on future strategies to address these gaps such as simplifying consent, expanding recruitment sites, collaborating with clinical, academic and public institutions, and raising public awareness of the role of the CHM Biobank. Conclusions: From the models employed over the past 5 years, it is evident that recruitment is most effective when patients perceive a direct benefit, such as involvement in active projects. These strategies outlined in the discussion are crucial for ensuring the CHM Biobank’s sustainability, diversity, and its impact on scientific research and patient outcomes in SA.

  • Medical Biorepositories of South Africa: Establishing a Medical Biorepository Network in South Africa to Advance Health Research

    by Engela Helena Conradie, Dominique Elizabeth Anderson, Warren Oswald Fransman, Albe Carina Swanepoel, Mandile Samantha Thobela, Ciara Staunton, Faghri February, Micheline Sanderson, Bonginkosi Mthandeni Duma, Mantombi Rebecca Maseme, et al.

    Biobanking is crucial for advancing medical research and personalized medicine, offering high-quality biospecimens for studies on biomarkers, drug development, and diagnostics. Despite its global potential, challenges such as fragmented governance and varying standards hinder biorepository collaboration, particularly in South Africa (SA). A unified national biobank network could enhance research and healthcare by improving biospecimen access, ethical governance, and collaboration. Global biobank networks offer models for standardization, data sharing, and international cooperation. SA can benefit from these models by creating a centralized biobank platform, promoting capacity building, and fostering regional and global partnerships. To address the challenges SA faces regarding biobanking, the Medical Biobanks Cluster established a network named Medical Biorepositories of SA (MBirSA), which seeks to build a cohesive network of medical biorepositories in SA. Through this network, it plans to foster an inclusive culture of biospecimen and data protocol harmonization, while encouraging adherence to legal, ethical, and quality best practices and standards. The network aims to bring stakeholders together, increasing visibility and transparency, and encouraging sector-wide collaboration. MBirSA also aims to offer training to build capacity in global best practices, aid in the development of dependable biorepository infrastructure, and promote research partnerships to enhance healthcare advancements.


  • Open Access

    Feasibility of NAD(P)/NAD(P)H as redox agents in enzymatic plasmonic gold nanostar assays for galactose quantification

    by Tozivepi Aaron Munyayi, Danielle Wingrove Mulder, Engela Helena Conradie, Barend Christiaan Vorster

    Plasmonic colorimetric sensors have emerged as powerful analytical tools in biochemistry due to their localized surface plasmon resonance extinction in the visible range. Here, we describe the feasibility of NAD(P)/NAD(P)H as redox agents in enzymatic plasmonic gold nanostar (AuNS) assays for galactose quantification using three model enzymes, GalDH, AR and GalOx, immobilized separately on polyvinylpyrrolidone-capped AuNS scaffolds. These highly specific, sensitive and selective bioassays induce the transformation of AuNS into quasi-spherical nanoparticles during the biorecognition of galactose in water and synthetic blood matrices. As a result, using our inexpensive and simple AuNS plasmon bioassays, the presence of galactose may be detected spectrophotometrically and by the naked eye.


  • Open Access

    The chemical composition and fluxes of atmospheric wet deposition at four sites in South Africa

    by E.H. Conradie, P.G. Van Zyl, J.J. Pienaar, J.P. Beukes, C. Galy-Lacaux, A.D. Venter, G.V. Mkhatshwa